Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Earnings Releases

Nexgel
Regional

Hydrogel Innovator NEXGEL Posts Steady Q3 as Margin Gains Offset Flat Revenue

November 18, 2025November 17, 2025 - by Timothy Alexander

LANGHORNE, PA — NEXGEL, Inc. (Nasdaq: NXGL) reported third quarter 2025 results showing stable revenue and improved margins as the hydrogel manufacturer continued to advance both its contract manufacturing and …

Hydrogel Innovator NEXGEL Posts Steady Q3 as Margin Gains Offset Flat Revenue Read More

Palvella Therapeutics
Finance

Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly

November 18, 2025November 17, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported third-quarter results and detailed an intensifying slate of clinical milestones as its QTORIN platform advances across four rare dermatologic diseases — …

Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly Read More
Passage Bio
Regional

Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates

November 18, 2025November 17, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported third-quarter financial results and outlined steady progress across its upliFT-D gene therapy program, positioning the company for critical regulatory and clinical …

Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates Read More

Orchestra BioMed Holdings
Regional

Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials

November 18, 2025November 17, 2025 - by Timothy Alexander

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported third-quarter financial results and detailed a series of strategic and regulatory milestones that collectively secured more than $147 million …

Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials Read More
Mineralys Therapeutics
Regional

Mineralys Nears Pivotal FDA Filing as Hypertension Drug Lorundrostat Advances

November 18, 2025November 17, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported third-quarter financial results and said it is preparing to submit a New Drug Application (NDA) for its lead candidate, lorundrostat, by …

Mineralys Nears Pivotal FDA Filing as Hypertension Drug Lorundrostat Advances Read More

ArriVent BioPharma
Regional

ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam

November 18, 2025November 17, 2025 - by Timothy Alexander

NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported third-quarter financial results and outlined major clinical milestones that position the company for a pivotal two-year stretch focused on advancing …

ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam Read More
The Chemours Company
Regional

Chemours Posts Solid Q3 as Refrigerants Surge and Other Segments Struggle

November 18, 2025November 16, 2025 - by Timothy Alexander

WILMINGTON, DE — The Chemours Company delivered a mixed third quarter, with strong refrigerant demand helping offset weakness across its titanium dioxide and advanced materials businesses.

Chemours Posts Solid Q3 as Refrigerants Surge and Other Segments Struggle Read More

Qnity Electronics
Regional

Qnity Posts Strong Q3 Gains as Newly Independent Chip Supplier Raises 2025 Outlook

November 18, 2025November 16, 2025 - by Timothy Alexander

WILMINGTON, DE — Qnity Electronics, Inc. (NYSE: Q), newly spun off from DuPont and now a standalone S&P 500 component, reported solid estimated third-quarter 2025 results, highlighted by double-digit sales …

Qnity Posts Strong Q3 Gains as Newly Independent Chip Supplier Raises 2025 Outlook Read More
Trinseo
Finance

Trinseo’s Deeper Loss Spurs Aggressive Cuts as Demand Weakens Again

November 18, 2025November 16, 2025 - by Timothy Alexander

WAYNE, PA — Trinseo (NYSE: TSE) reported another challenging quarter as soft global demand, pricing pressure in Europe, and lower equity income weighed heavily on results, pushing the specialty materials …

Trinseo’s Deeper Loss Spurs Aggressive Cuts as Demand Weakens Again Read More
Cabaletta Bio
Regional

Cabaletta Bio’s Bold Autoimmune Push Raises Big Questions About the Future of CAR T

November 18, 2025November 17, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported third-quarter results and outlined major clinical and regulatory milestones that position its lead therapy, rese-cel, as a potential first-in-class CAR T …

Cabaletta Bio’s Bold Autoimmune Push Raises Big Questions About the Future of CAR T Read More

Posts pagination

Previous 1 … 25 26 27 … 61 Next

Trending News

  • Chester County Trauma Coalition Marks Decade of Community Work

  • Philadelphia Man Indicted in Mosque Arson Civil Rights Case

  • Scooter Getaway? Man Charged in Wilmington Burglary Spree

  • Who Shot an Uber Driver Through Her Window in Philadelphia?

  • McCormick, Fetterman Target Addiction Workforce Shortage

Subscribe for Updates

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

ACEs anniversary

Chester County Trauma Coalition Marks Decade of Community Work

August 7, 2026August 7, 2026

Legal

Philadelphia Man Indicted in Mosque Arson Civil Rights Case

August 7, 2026August 7, 2026

Eric Jackson

Scooter Getaway? Man Charged in Wilmington Burglary Spree

August 7, 2026August 7, 2026

Copyright © 2026 MyChesCo.